An important characteristic of an antibody is its Fc effector function. Antibodies can be engineered to obtain the desired binding of the Fc region to Fc receptors expressed on effector cells. Hence, it is crucial to evaluate the binding interaction of mAbs/ADC with Fc receptors in the early phase of drug development to understand the potential biological activity of the product in vivo.
Surface Plasmon Resonance (SPR) is a powerful technique to establish binding kinetics in real-time, label-free, and high sensitivity with low sample consumption. Along with target antigen binding, it is crucial to evaluate the binding interaction of antibodies and ADCs with Fc receptors. Our SPR case studies investigated the impact on binding kinetics of ADCs with different linkers and the binding interactions of SARS-CoV-2 spike protein variants and evaluated the neutralizing ability of therapeutic mAbs. SPR characterization can be facilitated in all stages of the product life cycle to ensure the quality and safety of mAbs and ADCs.
Highlights of this webinar:
Helen Hsu, Ph.D.
Principal Scientist, Process and Analytical Development
Helen joined MilliporeSigma in 2017 and joined the process and analytical development team in St. Louis in September 2020. She has been leading the binding assay development, focusing on Surface Plasmon Resonance (SPR)-based assays to characterize biologics including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). She received a Ph.D. in chemistry focused on biosensor development from Massey University (New Zealand) and completed her postdoctoral research at Durham University (United Kingdom).
To continue reading please sign in or create an account.Don't Have An Account?